Dihydrocodeine BP 30mg
Brand name: Dihydrocodeine BP 30 mg by Accord Healthcare UK Ltd
Treatment: Moderate to severe pain relief
Quantity per pack: 28 x 30 mg tablets
Price per pill: £1.58
Active Ingredient: Dihydrocodeine
Dihydrocodeine BP 30 mg is a drug identified as an opioid. These Opioids belong to a group of medicines called analgesics, which are more commonly known to the general public as painkillers. Their most common use is mainly to relieve moderate to severe pain. This medicine is effective in all painful conditions where an alert patient is desired, such as:
- chronic rheumatoid arthritis
- arthritis of the spine
- peripheral vascular disease
- post-herpetic neuralgia
- Paget’s disease
- malignant disease
- post-operative pain.
Dihydrocodeine BP 30mg tablets cause little or no respiratory depression. For this reason, it is used to relieve post-operative pain, as it may help to reduce the risk of chest complications.
Before any individual thinks about starting treatment with opioids, one is strongly recommended to consult their doctor or GP. They should make an appointment to discuss putting in place a strategy for when the treatment using Dihydrocodeine BP 30 mg is coming to an end. This is in order to minimise the risk of any addiction and drug withdrawal syndrome.
The analgesic effect is not materially enhanced by increasing the dose. In severe cases the interval between doses should be reduced to obtain the requisite analgesic cover.
Adults and children over 12 years: 1 tablet every four to six hours or at the discretion of a doctor or your GP. Maximum dose in 24 hours is 180 mg (6 tablets).
Under 12 years old: A more suitable dosage form is recommended for children under 12 years (e.g. elixir). Consult a doctor or your GP.
Elderly: Dosage should be reduced in the elderly. Consult a doctor or your GP.
Method of administration
To be taken orally, swallowed whole and washed down with water. It is also recommended that this product should be taken during or after food.
• Hypersensitivity to the active substance or to any excipients
• Respiratory depression
• Obstructive airways disease
• Acute alcoholism
• Risk of paralytic ileus
• Head injuries or conditions in which intracranial pressure is raised.
Special warnings and precautions for use
For all patients, prolonged use of this product may lead to drug dependence (addiction). Even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder. Including alcohol misuse or mental health disorder (e.g., major depression). Therefore, additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse. A comprehensive patient history should be taken to document concomitant medications. This is including over-the-counter medicines, medicines obtained on-line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use. Thus, they could express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing a tolerance to the drug. The risks of developing tolerance should be explained to the patient.
Overuse or misuse of this drug may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction. The clinical need for analgesic treatment should be reviewed regularly.
Drug withdrawal syndrome
Before starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with Dihydrocodeine Tablets 30mg.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following:
Other symptoms may also develop including:
- abdominal cramps
- increased blood pressure
- increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia may be diagnosed if patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may lessen with a reduction of dosage.
Dihydrocodeine BP 30mg should be given in reduced doses or with caution to patients with asthma and decreased respiratory reserve. Avoid use during an acute asthma attack.
Dihydrocodeine should be avoided, or the dose reduced in patients with hepatic or renal impairment.
Dihydrocodeine should be given in reduced doses or with caution to:
- debilitated patients
- adrenocortical insufficiency
- prostatic hyperplasia
- urethral stricture
- inflammatory or obstructive bowel disorders
- hypothyroidism or convulsive disorders.
However, these conditions should not necessarily be a deterrent to use in palliative care. Alcohol should be avoided whilst under treatment with dihydrocodeine.